PEGCETACOPLAN

Information current as at: 1 August 2026

The pharmaceutical company has advised that it is not proceeding in the PBS listing process at this time. The process for listing this medicine has ceased.

Legend:

Completed N In progress

Not applicable N Yet to commence

Submission Details

Brand name:: Syfovre®
Form and strength:: Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:: APELLIS AUSTRALIA PTY LTD
Condition/indication: (therapeutic use): Bilateral geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
Listing requested:: Please see PSD for more information
Funding program:: Please see PSD for more information
Request authority level:: Please see PSD for more information
PBAC Submission type:: New PBS listing (–)
Comment:: --
Other PBAC consideration:: --

Progress Details

1Submission received for:: November 2025 PBAC meeting
2Opportunity for consumer comment:: Has not yet commenced
3PBAC meeting:: Has not yet occurred
4PBAC outcome published:: Recommended (see PBAC Outcomes)
Notice of intent submitted:: Awaiting lodgement from pharmaceutical company
5Lodgement of required documentation:: Has not yet commenced
6Agreement to listing arrangements:: Has not yet commenced
7Government processes:: Has not yet commenced
8Medicine listed on the PBS:: Has not yet occurred

Glossary

PBAC Outcome

PBAC Recommendation:

Please see the Outcomes from the relevant meeting for more information

Public Summary Document:

PBAC Public Summary Documents – November 2025

Case ID

a1115

Page last updated

31 July 2026

Return to the Medicine Status Listing

v.9.19